Currently, 1 in 7 men in Europe will develop detectable prostate cancer before the age of 85. More than two million men in Europe are living with this disease, today. (Reference: Eurostats)
In light of Prostate Cancer Awareness Month, EORTC aims at raising awareness about prostate cancer and the importance of international academic research. The webinar speakers include prostate cancer and quality of life experts, as well as representatives from a patient organization (Europa Uomo).
Titled “ARE WE MEASURING THE QUALITY OF LIFE OF PROSTATE CANCER PATIENTS EFFECTIVELY?”, the webinar will focus on Europa Uomo’s survey results, which indicate that any treatment apart from active surveillance may negatively affect quality of life, and that for many men these effects may be greater than previously thought.
EORTC quality of life group have been developing questionnaires for clinical trials over 40 years, with the EORTC QLQ-C30 and the EORTC QLQ-PR25 being used to evaluate the quality of life issues among prostate cancer patients. These validated questionnaires and its availability in various languages provide information on the benefit-risk assessment of prostate cancer treatments from the perspective of the patients.
Date: November 5th
Time: 12:30 to 13:30 p.m. CET
Don’t miss out